Learn more about investing in Diadem Biotherapeutics

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
We don’t spam. Our Privacy Policy and Cookie Policy apply. The site is protected by reCAPTCHA.
Diadem Biotherapeutics
Diadem Biotherapeutics
Engineering the next class of biologics to treat chronic inflammatory diseases
CONTACT COMPANY
INVESTOR INQUIRIES
Biopharma Human Health Therapeutics IBSF09 2019 Seed COVID-19 Response Human Health 100 United States
* Data source: Crunchbase
Founded
2019
Employees*
2-10
Funding to Date*
undisclosed
Website
diadembio.com
* Data source: Crunchbase
Dr. Mickey Pentecost, CEO
"Because exosomes are remarkably robust entities, we're looking at various delivery formats including inhalable."
Exosome therapeutic delivery market is expected to reach $30B by 2026, by a 22% CAGR

Diadem Biotherapeutics, Inc. is a platform therapeutics company developing a broad pipeline of first-in-class immunotherapies. Diadem is engineering exosomes to be inhalable cell-specific immune modulators. Exosomes are small, virus-sized particles released by cells to communicate throughout the body.

Leveraging expertise in genetic engineering and scalable bioprocessing, Diadem is developing cell secreted nanovesicles precisely engineered to deliver signals that mimic natural cell-to-cell signaling. Diadem’s unique approach enables precise modulation of targets that play a role in chronic inflammation, autoimmune diseases and immune control of cancers, addressing some critical unmet clinical needs. For more information, visit www.diadembio.com.

Team
Woytek Bartkowski
CTO & Co-Founder
Mickey Pentecost
CEO & Co-Founder
x-logo
Company News
Yahoo Finance | September 14, 2021
Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The …

Amgen (NASDAQ: AMGN) and The Lundquist Institute today announced that Diadem Biotherapeutics, Inc., has been awarded the first Amgen Golden Ticket in Southern California. Diadem will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen’s scientific and business leaders.
SynBioBeta | February 11, 2020
IndieBio’s Class Nine: Archetypes of Engineering Biology

On February 6, 2020, the eleven members of IndiBio’s Class Nine took the stage, revealing the ways they are engineering biology to optimize our immune systems, leverage the microbes that call our bodies home, make food ingredients and plastics more sustainable, and solve food production challenges.
YahooFinance | November 08, 2019
QB3 Congratulates Startups Selected for 2019 Biotech/Biopharma Pitch Summit Cohort

SAN FRANCISCO, Nov. 8, 2019 /PRNewswire/ — QB3 is proud to announce the 2019 cohort of the annual QB3 Biotech/Biopharma Pitch Summit, a group of early-stage companies chosen for their innovative technologies and potential market impact. This is the third year of the competition, which is open to life
More Companies
Cayuga Biotech
Convalesce Inc
Particella
SEE ALL COMPANIES